These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 25834026)
41. Cancer drug offers effective, cheaper option for AMD. Stephenson J JAMA; 2011 May; 305(20):2053-4. PubMed ID: 21610231 [No Abstract] [Full Text] [Related]
42. Experience of New Brunswick ophthalmologists using intravitreal anti-vascular endothelial growth factor. Giberson M; Taylor V Can J Ophthalmol; 2015 Oct; 50(5):393-4. PubMed ID: 26455977 [No Abstract] [Full Text] [Related]
43. Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials. Chen G; Li W; Tzekov R; Jiang F; Mao S; Tong Y Retina; 2015 Feb; 35(2):187-93. PubMed ID: 25105318 [TBL] [Abstract][Full Text] [Related]
44. Re: Berg et al.: Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol (Ophthalmology 2015;122:146-52). Avery RL Ophthalmology; 2016 Feb; 123(2):e14-e16. PubMed ID: 26802717 [No Abstract] [Full Text] [Related]
45. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model. Patel JJ; Mendes MA; Bounthavong M; Christopher ML; Boggie D; Morreale AP J Eval Clin Pract; 2012 Apr; 18(2):247-55. PubMed ID: 20846318 [TBL] [Abstract][Full Text] [Related]
46. Shifting exudative age-related macular degeneration patients to ranibizumab after insufficient response to bevacizumab. de Geus SJ; Jager MJ; Luyten GP; Dijkman G Acta Ophthalmol; 2013 Aug; 91(5):e411-3. PubMed ID: 23551594 [No Abstract] [Full Text] [Related]
47. Age-related macular degeneration, anti-VEGF therapy, and ophthalmic imaging: is there a best practice? Han DP JAMA Ophthalmol; 2013 Sep; 131(9):1124-6. PubMed ID: 23744293 [No Abstract] [Full Text] [Related]
48. By the way, doctor. My 78-year-old husband has wet macular degeneration. He is being treated with a drug called Avastin. Is that a good choice? Heier JS Harv Health Lett; 2010 May; 35(7):6. PubMed ID: 20583361 [No Abstract] [Full Text] [Related]
49. [Initial experience with aflibercept in the management of patients with wet age-related macular degeneration refractory to ranibizumab and/or bevacizumab]. Cervera RE; Castro V; Montero J; Torralba C; Gracia A Arch Soc Esp Oftalmol; 2014 Jan; 89(1):42-3. PubMed ID: 24269436 [No Abstract] [Full Text] [Related]
50. Comparison of outcomes after switching treatment from intravitreal bevacizumab to ranibizumab in neovascular age-related macular degeneration. Kent JS; Iordanous Y; Mao A; Powell AM; Kent SS; Sheidow TG Can J Ophthalmol; 2012 Apr; 47(2):159-64. PubMed ID: 22560422 [TBL] [Abstract][Full Text] [Related]
51. [A new drug for macular degeneration. A breakthrough accomplished (interview by Waldtraud Paukstadt)]. Holz FG MMW Fortschr Med; 2007 Jan; 149(3):13-4. PubMed ID: 17619376 [No Abstract] [Full Text] [Related]
52. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G; Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488 [TBL] [Abstract][Full Text] [Related]
53. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630 [TBL] [Abstract][Full Text] [Related]
54. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Berg K; Pedersen TR; Sandvik L; Bragadóttir R Ophthalmology; 2015 Jan; 122(1):146-52. PubMed ID: 25227499 [TBL] [Abstract][Full Text] [Related]